Advanced in Myeloproliferative Neoplasms (MPN)

Dr. Nashat Y. Gabrail

Hematology | Oncology

4875 Higbee Ave Nw,

Canton, OH

Clinical Trials:Currently Recruiting for 10 Trials

Accepting New Patients

Advanced in Myeloproliferative Neoplasms (MPN)

4875 Higbee Ave Nw,

Canton, OH

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nashat Gabrail is a Hematologist and an Oncologist in Canton, Ohio. Dr. Gabrail is rated as an Advanced provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Blood Clots, Multiple Myeloma, Lung Cancer, and Relapsed Refractory Multiple Myeloma (RRMM). Dr. Gabrail is currently accepting new patients.

His clinical research consists of co-authoring 43 peer reviewed articles and participating in 73 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Myeloproliferative Neoplasms (MPN).

Specialties

Hematology

Oncology

Licenses

Specialist in OH

Hospital Affiliations

Mercy Medical Center

Aultman Hospital

Languages Spoken

English

Arabic

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem

Blue Cross Blue Shield

Blue Shield of California

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE-MEDICAID PLAN
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Buckeye Health Plan

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE-MEDICAID PLAN

CareSource

Cigna

Devoted Health

MEDICARE MAPD
OTHER MEDICARE

First Health

INSURANCE PLAN
MEDICARE PDP
PPO

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Highmark

Humana

HMO
INDEMNITY
POS
PPO

Managed Medicaid

OTHER MANAGED MEDICAID

Medical Health

Medical Mutual

Oscar

Primetime Health Plan

MEDICARE MAPD
MEDICARE PDP
OTHER MEDICARE PART D

Spectrum Priority Health

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER COMMERCIAL

SummaCare

TeamCare

OTHER COMMERCIAL

The Health Plan

HMO
MANAGED MEDICAID PLAN
OTHER MEDICARE PART D

UnitedHealthcare

UPMC

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 19 Less Insurance Carriers -

Locations

4875 Higbee Ave Nw, Canton, OH 44718

Call: 330-492-3345

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

71 Clinical Trials

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)

Enrollment Status: Recruiting

Publish Date: October 03, 2025

Intervention Type: Drug

Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin

Study Phase: Phase 2/Phase 3

Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma

Enrollment Status: Recruiting

Publish Date: October 01, 2025

Intervention Type: Combination product, Drug

Study Drugs: Tazemetostat, Lenalidomide, Rituximab

Study Phase: Phase 3

An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer

Enrollment Status: Recruiting

Publish Date: September 12, 2025

Intervention Type: Drug

Study Phase: Phase 3

RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Enrollment Status: Recruiting

Publish Date: July 28, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Enrollment Status: Recruiting

Publish Date: July 10, 2025

Intervention Type: Drug

Study Drug: Repotrectinib

Study Phase: Phase 1/Phase 2

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma

Enrollment Status: Recruiting

Publish Date: June 24, 2025

Intervention Type: Drug

Study Drug: VMD-928

Study Phase: Phase 1

A Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Chiauranib for the Treatment of Advanced Solid Tumors and Relapsed/Refractory SCLC

Enrollment Status: Recruiting

Publish Date: July 16, 2024

Intervention Type: Drug

Study Drug: Chiauranib

Study Phase: Phase 1/Phase 2

A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis

Enrollment Status: Recruiting

Publish Date: May 10, 2024

Intervention Type: Drug

Study Drug: TL-895

Study Phase: Phase 2

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Solid Tumors

Enrollment Status: Recruiting

Publish Date: May 31, 2023

Intervention Type: Drug

Study Drug: EMB-01

Study Phase: Phase 1/Phase 2

A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)

Enrollment Status: Recruiting

Publish Date: April 07, 2023

Intervention Type: Drug

Study Drugs: DPX-Survivac, Pembrolizumab, CPA

Study Phase: Phase 2

Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer

Enrollment Status: Completed

Publish Date: October 14, 2025

Intervention Type: Drug

Study Drugs: Niraparib, TSR-042 Anti-PD-1 Antibody, Bevacizumab, TSR-022 Anti-TIM-3 Antibody, Carboplatin, Pemetrexed, Nab-Paclitaxel

Study Phase: Phase 1

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)

Enrollment Status: Completed

Publish Date: October 08, 2025

Intervention Type: Drug

Study Drugs: CPI-0610, Rituximab

Study Phase: Phase 1/Phase 2

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy

Enrollment Status: Completed

Publish Date: September 25, 2025

Intervention Type: Drug

Study Drugs: Trilaciclib, Topotecan

Study Phase: Phase 1/Phase 2

A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, EGFR, or ALK Inhibitor.

Enrollment Status: Completed

Publish Date: September 25, 2025

Intervention Type: Biological

Study Drugs: CAB-AXL-ADC, PD-1 Inhibitor

Study Phase: Phase 2

A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Enrollment Status: Active_not_recruiting

Publish Date: September 24, 2025

Intervention Type: Drug

Study Drug: HBI-2376

Study Phase: Phase 1

A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects

Enrollment Status: Completed

Publish Date: September 15, 2025

Intervention Type: Drug

Study Phase: Phase 1

A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Enrollment Status: Active_not_recruiting

Publish Date: September 09, 2025

Intervention Type: Drug

Study Drugs: Tucatinib, Trastuzumab, Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine

Study Phase: Phase 2

A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers

Enrollment Status: Completed

Publish Date: August 11, 2025

Intervention Type: Biological

Study Drugs: Enoblituzumab, Pembrolizumab, MGA012 Anti-PD-1 Antibody

Study Phase: Phase 1

An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies

Enrollment Status: Completed

Publish Date: May 11, 2025

Intervention Type: Drug

Study Drugs: SEA-CD40, Pembrolizumab, Pemetrexed, Carboplatin

Study Phase: Phase 2

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Enrollment Status: Terminated

Publish Date: April 23, 2025

Intervention Type: Drug, Device

Study Phase: Phase 2

FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Enrollment Status: Terminated

Publish Date: March 24, 2025

Intervention Type: Drug

Study Phase: Phase 2/Phase 3

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Enrollment Status: Completed

Publish Date: March 17, 2025

Intervention Type: Drug, Biological

Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine

Study Phase: Phase 3

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

Enrollment Status: Terminated

Publish Date: March 10, 2025

Intervention Type: Drug

Study Drug: Ladiratuzumab Vedotin

Study Phase: Phase 2

A Phase 1/2, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 with and Without Chemotherapy in the Treatment of Subjects with Solid Tumors

Enrollment Status: Completed

Publish Date: December 31, 2024

Intervention Type: Drug

Study Drug: Abraxane

Study Phase: Phase 1/Phase 2

A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma

Enrollment Status: Completed

Publish Date: December 24, 2024

Intervention Type: Drug

Study Drugs: TAK-573, Dexamethasone

Study Phase: Phase 1/Phase 2

An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered With Encorafenib and Binimetinib in Patients With BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: September 27, 2024

Intervention Type: Drug

Study Drugs: losartan, Dextromethorphan, Caffeine, Omeprazole, Midazolam, Rosuvastatin, Bupropion Immediate Release (IR), Encorafenib, Binimetinib, Modafinil

Study Phase: Phase 1

A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)

Enrollment Status: Completed

Publish Date: August 27, 2024

Intervention Type: Drug

Study Drugs: Cedazuridine, Decitabine

Study Phase: Phase 3

A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: August 09, 2024

Intervention Type: Drug

Study Phase: Phase 1

A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy

Enrollment Status: Completed

Publish Date: July 26, 2024

Intervention Type: Drug

Study Drug: Crofelemer [Mytesi]

Study Phase: Phase 3

A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma

Enrollment Status: Terminated

Publish Date: July 09, 2024

Intervention Type: Drug

Study Drugs: ACY-241, Pomalidomide, Dexamethasone

Study Phase: Phase 1

A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Enrollment Status: Completed

Publish Date: July 01, 2024

Intervention Type: Drug

Study Drugs: TJ011133, Pembrolizumab, Rituximab

Study Phase: Phase 1

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy

Enrollment Status: Active_not_recruiting

Publish Date: April 30, 2024

Intervention Type: Biological, Drug

Study Drugs: Tomivosertib, Pembrolizumab

Study Phase: Phase 2

A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

Enrollment Status: Completed

Publish Date: March 28, 2024

Intervention Type: Drug

Study Drugs: CDX-1140, CDX-301, Pembrolizumab, Gemcitabine, Nab-Paclitaxel

Study Phase: Phase 1

An Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC Who Failed Either Abiraterone or Enzalutamide

Enrollment Status: Completed

Publish Date: February 12, 2024

Intervention Type: Drug

Study Drug: GT0918

Study Phase: Phase 2

A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors

Enrollment Status: Terminated

Publish Date: February 02, 2024

Intervention Type: Drug, Biological

Study Drugs: OSE2101, Docetaxel, Pemetrexed

Study Phase: Phase 3

A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Completed

Publish Date: January 25, 2024

Intervention Type: Drug, Radiation

Study Phase: Phase 1/Phase 2

A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Enrollment Status: Completed

Publish Date: December 21, 2023

Intervention Type: Drug

Study Phase: Phase 3

A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)

Enrollment Status: Completed

Publish Date: September 21, 2023

Intervention Type: Biological, Drug

Study Drugs: Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed

Study Phase: Phase 1/Phase 2

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants

Enrollment Status: Terminated

Publish Date: July 24, 2023

Intervention Type: Drug

Study Drug: Casirivimab+Imdevimab

Study Phase: Phase 3

A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: June 07, 2023

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Multicenter Phase 2, Open Label Study of Intratumoral Tavokinogene Telseplasmid (Tavo, pIL-12) + Electroporation With Pembrolizumab in Patients With Stage 3/4 Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment

Enrollment Status: Unknown

Publish Date: March 27, 2023

Intervention Type: Biological, Device

Study Drugs: Tavokinogene Telseplasmid, Pembrolizumab

Study Phase: Phase 2

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone

Enrollment Status: Completed

Publish Date: March 22, 2023

Intervention Type: Drug

Study Phase: Phase 2

A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy

Enrollment Status: Unknown

Publish Date: March 08, 2023

Intervention Type: Drug

Study Drugs: Pyrotinib, Docetaxel

Study Phase: Phase 3

A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation

Enrollment Status: Completed

Publish Date: January 26, 2023

Intervention Type: Drug

Study Phase: Phase 2

Phase I Study of Intratumoral CAVATAK® (Coxsackievirus A21) and Pembrolizumab in Subjects With Advanced Melanoma (VLA-011 CAPRA)

Enrollment Status: Completed

Publish Date: January 17, 2023

Intervention Type: Drug, Biological

Study Phase: Phase 1

A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody

Enrollment Status: Completed

Publish Date: November 22, 2022

Intervention Type: Drug

Study Drugs: Melphalan Flufenamide (Melflufen), Dexamethasone

Study Phase: Phase 2

An Open-Label Study to Assess the Safety, Tolerability, and Efficacy of Active Immunotherapy With Dose Escalation and Cohort Expansion of OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal, or Breast Cancer Subjects

Enrollment Status: Completed

Publish Date: October 03, 2022

Intervention Type: Drug

Study Phase: Phase 1

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)

Enrollment Status: Completed

Publish Date: September 15, 2022

Intervention Type: Drug

Study Phase: Phase 2

A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma (ILLUMINATE-204)

Enrollment Status: Completed

Publish Date: August 03, 2022

Intervention Type: Drug

Study Phase: Phase 2

A Phase I, First-In-Human, Randomized, Single Ascending Dose Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19

Enrollment Status: Withdrawn

Publish Date: May 18, 2022

Intervention Type: Other, Drug

Study Phase: Phase 1

View 40 Less Clinical Trials

43 Total Publications

Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.

Journal: Med (New York, N.Y.)

Published: April 16, 2025

View All 43 Publications

Similar Doctors

Elite in Myeloproliferative Neoplasms (MPN)

Dr. Aaron Gerds

Hematology Oncology | Hematology | Oncology

Elite in Myeloproliferative Neoplasms (MPN)

Dr. Aaron Gerds

Hematology Oncology | Hematology | Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue,

Cleveland, OH

(45.9 miles away)

866-223-8100

Experience:

23+ years

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Aaron Gerds is a Hematologist Oncology specialist and a Hematologist in Cleveland, Ohio. Dr. Gerds has been practicing medicine for over 23 years and is rated as an Elite provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Myelofibrosis, Myeloproliferative Neoplasms (MPN), Polycythemia Vera, Bone Marrow Aspiration, and Bone Marrow Transplant.

Advanced in Myeloproliferative Neoplasms (MPN)

Dr. Rebecca B. Klisovic

Oncology | Hematology

Advanced in Myeloproliferative Neoplasms (MPN)

Dr. Rebecca B. Klisovic

Oncology | Hematology

University Hospitals Medical Group Inc

11100 Euclid Ave,

Cleveland, OH

(46.2 miles away)

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Rebecca Klisovic is an Oncologist and a Hematologist in Cleveland, Ohio. Dr. Klisovic is rated as a Distinguished provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). Her top areas of expertise are Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Klisovic is currently accepting new patients.

Advanced in Myeloproliferative Neoplasms (MPN)

Dr. John Molina

Hematology | Pediatric Hematology Oncology | Oncology

Advanced in Myeloproliferative Neoplasms (MPN)

Dr. John Molina

Hematology | Pediatric Hematology Oncology | Oncology

Cleveland Clinic Main Campus

9500 Euclid Avenue,

Cleveland, OH

(46.0 miles away)

216-444-2200

Experience:

17+ years

Languages Spoken:

English, Spanish

See accepted insurances

John Molina is a Hematologist and a Pediatric Hematologist Oncology provider in Cleveland, Ohio. Dr. Molina has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia with Maturation, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

VIEW MORE MYELOPROLIFERATIVE NEOPLASMS (MPN) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gabrail's expertise for a condition

ConditionClose